Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M3,013Revenue (TTM) $M56.8Net Margin (%)-218.7Altman Z-Score21.3
Enterprise Value $M2,723EPS (TTM) $-2.5Operating Margin %-436.0Piotroski F-Score4
P/E(ttm)--Beneish M-Score36.8Pre-tax Margin (%)-215.3Higher ROA y-yY
Price/Book6.810-y EBITDA Growth Rate %6.6Quick Ratio5.3Cash flow > EarningsN
Price/Sales45.65-y EBITDA Growth Rate %35.4Current Ratio5.9Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-29.9Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-37.1Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M64.3ROIC % (ttm)-545.1Gross Margin Increase y-yN

Gurus Latest Trades with SRPT

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

SRPT is held by these investors:



SRPT: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
INGRAM DOUGLAS SPresident & CEO 2017-07-27Buy47,058$42.510.19view
Ruff ShamimSVP, Regulatory Affairs & Qual 2017-07-21Sell12,138$42.978.98view
Mahatme SandeshEVP, CFO & CBO 2017-07-20Sell50,000$4114.22view
Kaye Edward M. MDDirector 2017-07-20Sell10,000$4114.22view
Howton David TSVP, General Counsel 2017-07-20Sell25,000$4114.22view
Cumbo AlexanderSVP, Chief Commercial Officer 2017-07-20Sell5,918$4114.22view
Mahatme SandeshSenior Vice President, CFO 2016-10-17Sell30,000$50.08-6.49view
Kaye Edward M. MDPresident, CEO & CMO 2016-09-22Sell40,179$60-21.95view
Howton David TSVP, General Counsel 2016-09-22Sell7,000$60-21.95view
Ruff ShamimSVP, Regulatory Affairs & Qual 2016-09-22Sell7,311$60-21.95view

Press Releases about SRPT :

Quarterly/Annual Reports about SRPT:

News about SRPT:

Articles On GuruFocus.com
Sarepta Therapeutics to Ring Nasdaq Stock Market Closing Bell in Recognition of World Duchenne Aware Sep 06 2017 
Sarepta Therapeutics Announces Positive Results in Its Study Evaluating Gene Expression, Dystrophin Sep 06 2017 
Sarepta Therapeutics, Inc. (Nasdaq: SRPT) to Ring The Nasdaq Stock Market Closing Bell Sep 05 2017 
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Aug 31 2017 
Sarepta Therapeutics to Present at Three Upcoming Investor Conferences Aug 24 2017 
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Jul 31 2017 
Sarepta Therapeutics Announces its Partner, Genethon, Published New Micro-Dystrophin Gene Therapy Da Jul 27 2017 
Sarepta Therapeutics Announces Pricing of $325 Million Public Offering of Common Stock Jul 24 2017 
Sarepta Therapeutics Announces Proposed $250 Million Public Offering of Common Stock Jul 24 2017 
Sarepta Therapeutics and Clinigen Launch a Managed Access Program to Treat Patients with Duchenne Mu Jul 19 2017 

More From Other Websites
See what the IHS Markit Score report has to say about Sarepta Therapeutics Inc. Sep 12 2017
What Analysts Recommend for BioMarin Pharmaceuticals in September Sep 11 2017
Sarepta Therapeutics Chart Patterns Look Good Sep 07 2017
Sarepta's Golodirsen Positive in DMD Study, Shares Soar Sep 07 2017
[$$] Sarepta: Turbocharge Returns With Options Sep 07 2017
Today's Research Reports on Stocks to Watch: Sarepta Therapeutics and Myriad Genetics Sep 07 2017
Sarepta’s positive trial results for new DMD treatment could reopen rare disease drug controversy Sep 07 2017
What Happened in the Stock Market Today Sep 06 2017
This Controversial Biotech May Yet Defy Its Skeptics Sep 06 2017
Can you trust Facebook? It's in the Blitz Sep 06 2017
We May Soon Learn Just How Flexible Scott Gottlieb's FDA Is Sep 06 2017
Is There Now An Opportunity In Sarepta Therapeutics Inc (SRPT)? Sep 06 2017
​Why Sarepta’s latest trial data may presage another FDA controversy Sep 06 2017
Why Sarepta Therapeutics Stock Is Rising Today Sep 06 2017
[$$] Soaring Sarepta Can Continue to Stay Hot Sep 06 2017
CEO defends $300,000-per-year cost for a drug for a rare form of muscular dystrophy Sep 06 2017
Stocks to Watch: Hewlett Packard Enterprise, Fiat Chrysler, Exxon Mobil, Sarepta Therapeutics, G-III... Sep 06 2017
Shares of drugmaker that targets gene mutations soar after positive study results Sep 06 2017
Sarepta Therapeutics to Ring Nasdaq Stock Market Closing Bell in Recognition of World Duchenne... Sep 06 2017

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}